EmeraMed Ltd is a biotechnology firm based in Lexington, KY, specializing in the development of Emeramide, a lipophilic antioxidant that passes the blood-brain barrier. With its ability to chelate heavy metals and capture free radicals, Emeramide aims to restore normal mitochondrial function and improve overall health, targeting the root cause of various diseases. The company has completed a Phase 2a clinical trial for COPD and is currently conducting preclinical studies for other indications, including its potential use in treating Covid-19.
EmeraMed is dedicated to revolutionizing healthcare with its safe and effective metal chelator and antioxidant, Emeramide. The company is actively seeking drug approval from the European Medical Agency (EMA) and the United States Food and Drug Administration (FDA). It is important to note that counterfeit versions of Emeramide are being illegally sold under different trade names, and EmeraMed is working closely with regulatory authorities to address this issue. With a mission to improve health and fight viral infections while removing heavy metals, EmeraMed is at the forefront of shaping the future of health.
Generated from the website